These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8091475)

  • 1. Can the cost of erythropoietin for cardiac surgery patients be justified?
    Strauss RG
    Transfusion; 1994 Sep; 34(9):835. PubMed ID: 8091475
    [No Abstract]   [Full Text] [Related]  

  • 2. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 3. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Vanscoy GJ
    Curr Med Res Opin; 2004 Sep; 20(9):1459-60; author reply 1462-3. PubMed ID: 15383195
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 6. A star rises, another fades.
    Neumann ME
    Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
    [No Abstract]   [Full Text] [Related]  

  • 7. A cost-effectiveness analysis of epoetin usage for patients with AIDS.
    Cantor SB; Carson RW; Spann SJ
    Pharmacoeconomics; 1993 Mar; 3(3):244-9. PubMed ID: 10146947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and economic repercussions of changing the erythropoietin administration route].
    Rodríguez JR; Ruiz E; Vázquez G; Ruiz Cicero E
    Nefrologia; 2005; 25(3):343-4. PubMed ID: 16053021
    [No Abstract]   [Full Text] [Related]  

  • 9. The possible effects of CMS's 'non-decision' on a national coverage decision for ESA therapy.
    Cotter D; Thamer M; Zhang Y
    Nephrol News Issues; 2011 Aug; 25(9):15-6, 18. PubMed ID: 21905526
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients.
    Tonelli M; Winkelmayer WC; Jindal KK; Owen WF; Manns BJ
    Kidney Int; 2003 Jul; 64(1):295-304. PubMed ID: 12787422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in end-stage renal disease.
    Bihl G
    S Afr Med J; 2002 Aug; 92(8):565. PubMed ID: 12244602
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug distribution and expenditure: the issue of epoetin in Italy.
    La Vecchia C; Franceschi S; Apolone G
    Eur J Public Health; 2003 Dec; 13(4):367. PubMed ID: 14703326
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin therapy for premature infants: cost without benefit?
    Zipursky A
    Pediatr Res; 2000 Aug; 48(2):136. PubMed ID: 10926284
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
    Nyvad O; Danielsen H; Madsen S
    Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and cost analysis of treating low birth weight infants with erythropoietin.
    Caplan M; Millard D
    J Pediatr; 1995 Oct; 127(4):672-3. PubMed ID: 7562305
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting.
    Kruep EJ; Basskin LE
    Am J Health Syst Pharm; 2005 Dec; 62(24):2597-603. PubMed ID: 16333057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
    Rodríguez Palomares JR; Fanlo B; Albarracín C; Junquera E
    Nefrologia; 2003; 23(2):181-2. PubMed ID: 12778887
    [No Abstract]   [Full Text] [Related]  

  • 18. Costs of epoetin in patients with AIDS.
    Henry DH
    Pharmacoeconomics; 1994 May; 5(5):446-7. PubMed ID: 10147234
    [No Abstract]   [Full Text] [Related]  

  • 19. Is the use of recombinant human erythropoietin in anaemia of prematurity cost-effective?
    Meyer MP; Haworth C; McNeill L
    S Afr Med J; 1996 Mar; 86(3):251-3. PubMed ID: 8658295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHARMAC and erythropoietin for cancer patients.
    Grocott R; Metcalfe S; Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2039. PubMed ID: 16807581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.